- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Management of rejection in patients following organ or tissue transplantation
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Tacrolimus – November 2019
Tacrolimus: Capsule 3 mg (once daily prolonged release); Advagraf XL®
Last updated
6 March 2020